0001501796
2026-05-04
2026-05-04
0001501796
1
2026-05-04
2026-05-04
0001501796
2
2026-05-04
2026-05-04
0001501796
3
2026-05-04
2026-05-04
0001501796
4
2026-05-04
2026-05-04
iso4217:USD
pure
0001501796
333-278253
S-3MEF
EX-FILING FEES
Common Stock, par value $0.00001 per share, issuable upon exercise of Pre-Funded Warrants
true
N/A
N/A
S-3
Aura Biosciences, Inc.
Equity
Common Stock, par value $0.00001 per share
true
Equity
Pre-funded warrants to purchase Common Stock
true
Equity
Unallocated (Universal) Shelf
true
49907450
0.0001381
6892.22
false
49907450
6892.22
0
0
6892.22
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">1</div> </td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;">The amount to be registered consists of up to $49,907,450.00 of an indeterminate amount of common stock, par<div style="display:inline;"> val</div>ue $0.00001 per share (the “Common Stock”), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants to purchase shares of the Company’s stock <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(“Pre-Funded</div> Warrants”) and shares issuable upon the exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants. Any securities registered hereunder may be sold separately or together with other securities registered hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> under the Securities Act of 1933, as amended. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Includes such indeterminate amount of common stock as may be issued from time to time upon exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants registered hereby, as the case may be. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants may be sold separately or together with any of the securities registered hereby and may be exercisable for shares of common stock registered hereby. Because the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants will provide a right only to purchase such securities offered hereunder, no additional registration fee is required. </div>